Top Markets
#1 Cortex Cortex +173.34%
#2 GEKKO GEKKO +52.86%
#3 Helium Helium +19.19%
#4 ADO Protocol ADO Protocol +18.03%
#5 Audiera Audiera +12.56%
#6 o1.exchange o1.exchange +11.76%
#7 Bless Bless +11.17%
#8 Seeker Seeker +10.51%
#9 Status Status +9.43%
#10 aelf aelf +8.71%
Coin of the day
Cortex Cortex
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals, Inc.

LBPH
Classement en actions #8563
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.
Prix de l'action
$59.98
Dernière synchronisation: 2024-12-13
Capitalisation boursière
$1.22B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Longboard Pharmaceuticals, Inc. (LBPH)

Catégorie

Healthcare
Bénéfices pour Longboard Pharmaceuticals, Inc. (LBPH)
Bénéfices en Sep 2024 TTM : $-76.34M
Selon les derniers rapports financiers de Longboard Pharmaceuticals, Inc., les bénéfices actuels de l'entreprise sont de $-76.34M. En 2022, l'entreprise a réalisé un bénéfice de $-43.95M, une diminution par rapport à celui de 2021 qui était de $-27.80M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Longboard Pharmaceuticals, Inc. de 2020 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
2026 (TTM) $-76.34M 40.28%
2023 $-54.42M 23.84%
2022 $-43.95M 58.09%
2021 $-27.80M 93.03%
2020 $-14.40M 0.00%
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -7,009.38%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -2,655.08%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 5,160.66%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 3,943.54%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH